

## Datasheet: AAI28AB

Description:	GOAT ANTI CHICKEN IgA:Alk. Phos.		
Specificity:	IgA		
Format:	Alk. Phos.		
Product Type:	Polyclonal Antibody		
lsotype:	Polyclonal IgG		
Quantity:	0.5 mg		

## **Product Details**

Applications	This product has been reported to work in the following applications. This information is derived			
	from testing within our laboratories, peer-reviewed publications or personal communications from			
	the originators. Please refer to references indicated for further information. For general protocol			
	recommendations, please visit www.bio-rad-antibodies.com/protocols.			

 Yes
 No
 Not Determined
 Suggested Dilution

 ELISA
 •
 1/1000 - 1/10000

 Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using the appropriate negative/positive controls.

Target Species	Chicken	
Product Form	Purified IgG conjugated to Alkaline Phosphatase - liquid	
Antiserum Preparation	Antisera to chicken IgA were raised by repeated immunisation of goa Purified IgG prepared by affinity chromatography.	at with highly purified antigen.
Buffer Solution	50mM HEPES, 0.1M NaCl, 1mM MgCl <sub>2</sub> , 0.1mM ZnCl <sub>2</sub>	
Preservative Stabilisers	0.09% Sodium Azide (NaN <sub>3</sub> ) 0.2% Bovine Serum Albumin	
Approx. Protein Concentrations	IgG concentration 0.5mg/ml	
Immunogen	Purified chicken IgA.	
Specificity	Goat anti Chicken IgA antibody recognizes chicken immunoglobuli reactivity with other chicken immunoglobulin classes in immunoelectr	
	Goat anti Chicken IgA antibody may react with IgA from other specie	?S.
References	1. Withanage, G.S. <i>et al.</i> (2005) Cytokine and chemokine responses primary <i>Salmonella enterica</i> serovar <i>Typhimurium</i> infection in the chi	

immunity to rechallenge. Infect Immun. 73 (8): 5173-82.

2. Singh, R. (2010) Immunogenicity and protective efficacy of virosome based vaccines against Newcastle disease. <u>Trop Anim Health Prod. 42: 465-71</u>

3. Wyszyśska A *et al.* (2004) Oral immunization of chickens with avirulent *Salmonella* vaccine strain carrying *C. jejuni* 72Dz/92 cjaA gene elicits specific humoral immune response associated with protection against challenge with wild-type *Campylobacter*. <u>Vaccine. 22 (11-12): 1379-89.</u>

 Beal, R.K. *et al.* (2005) A strong antigen-specific T-cell response is associated with age and genetically dependent resistance to avian enteric salmonellosis. <u>Infect Immun. 73: 7509-16.</u>
 Buckley, A.M. *et al.* (2010) Evaluation of live-attenuated *Salmonella* vaccines expressing

*Campylobacter* antigens for control of *C. jejuni* in poultry. <u>Vaccine. 28: 1094-105.</u>
6. Bérto Letícia Dal *et al.* (2015) Live and Inactivated *Salmonella enteritidis* Vaccines: Immune Mechanisms in Broiler Breeders World Journal of Vaccines. 05 (04): 155-164.

7. Beal, R.K. *et al.* (2004) Age at primary infection with *Salmonella enterica* serovar *Typhimurium* in the chicken influences persistence of infection and subsequent immunity to re-challenge. <u>Vet</u> <u>Immunol Immunopathol. 100 (3-4): 151-64.</u>

8. Park, S.I. *et al.* (2010) Immune response induced by ppGpp-defective *Salmonella enterica* serovar *Gallinarum* in chickens. J Microbiol. 48 (5): 674-81.

9. Beal RK *et al.* (2004) Temporal dynamics of the cellular, humoral and cytokine responses in chickens during primary and secondary infection with *Salmonella enterica* serovar *Typhimurium*. Avian Pathol. 33 (1): 25-33.

10. Zhang L *et al.* (2008) Enhancement of mucosal immune responses by intranasal co-delivery of Newcastle disease vaccine plus CpG oligonucleotide in SPF chickens *in vivo*. <u>Res Vet Sci. 85 (3):</u> 495-502.

11. Park, E.H. *et al.* (2014) Protective efficacy of a single dose of baculovirus hemagglutinin-based vaccine in chickens and ducks against homologous and heterologous H5N1 virus infections. <u>Viral</u> Immunol. 27 (9): 449-62.

12. Barrow, P.A. *et al.* (2004) Faecal shedding and intestinal colonization of *Salmonella enterica* in in-bred chickens: the effect of host-genetic background. <u>Epidemiol Infect. 132 (1): 117-26.</u>

13. Andersen, J.P. *et al.* (2013) No protection in chickens immunized by the oral or intra-muscular immunization route with *Ascaridia galli* soluble antigen. <u>Avian Pathol. 42 (3): 276-82.</u>

14. Koppad, S. *et al.* (2011) Calcium phosphate coupled Newcastle disease vaccine elicits humoral and cell mediated immune responses in chickens. <u>Res Vet Sci. 91 (3): 384-90.</u>

15. Rezar, V. *et al.* (2007) Dose-dependent effects of T-2 toxin on performance, lipid peroxidation, and genotoxicity in broiler chickens. <u>Poult Sci. 86 (6): 1155-60.</u>

16. Sadeyen JR *et al.* (2014) Analysis of immune responses induced by avian pathogenic *Escherichia coli* infection in turkeys and their association with resistance to homologous re-challenge. <u>Vet Res. 45: 19</u>.

 Barman, N. N. *et al.* (2014) Reflection of serum immunoglobulin isotypes in the egg yolk of laying hens immunized with enterotoxigenic *Escherichia coli* <u>Veterinary World. 7 (9): 749-753.</u>
 Salisbury Anne-Marie *et al.* (2014) *Salmonella* Virchow Infection of the Chicken Elicits Cellular and Humoral Systemic and Mucosal Responses, but Limited Protection to Homologous or Heterologous Re-Challenge Frontiers in Veterinary Science. 1: 6.

19. Radomska, K.A. *et al.* (2016) Chicken Immune Response after *In Ovo* Immunization with Chimeric TLR5 Activating Flagellin of Campylobacter jejuni. <u>PLoS One. 11 (10): e0164837.</u>

Storage	Store at +4°C. DO NOT FREEZE.		
	This product should be stored undiluted. Should this product contain a precipitate we recommend microcentrifugation before use.		
Shelf Life	12 months from date of despatch.		
Health And Safety	Material Safety Datasheet documentation #10089 available at:		

Informat	i <b>on</b> 10089: <u>ht</u>	tps://www.bio-r	9.pdf		
Regulato	ry For resea	arch purposes o			
North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50
	Email: antibody_sales_us@bio	-rad.com	Email: antibody_sales_uk@bio	-rad.com	Email: antibody_sales_de@bio-rad.com
			'M314076:180412'		
			Printed on 30 Apr 2018		

© 2018 Bio-Rad Laboratories Inc | Legal | Imprint

Page 3 of 3